Latest News

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Lymphoma Research, Lymphoma, Cancer, CAR-T cell therapy

Dana-Farber and Brigham and Women’s researchers laud FDA approval of CAR T-cell therapy for non-Hodgkin Lymphoma

Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women’s Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration (FDA) today. Dana-Farber/Brigham and Women’s Cancer Center, the only facility in the northeast to be part of the clinical trial, is one of a few locations certified to offer this new therapy nationwide.

Medicine

Channels:

Discovery of Peripheral Neuropathy Cause Suggests Potential Preventive Measures

In discovering how certain chemotherapy drugs cause the nerve damage known as peripheral neuropathy, researchers at Dana-Farber Cancer Institute have found a potential approach to preventing this common and troublesome side effect of cancer treatment.

Medicine

Channels:

New Biomarker Predicts Metastatic Prostate Cancers

leigh-ellis.jpg

Many prostate cancers, which generally are diagnosed in older men, are "indolent," slow-growing tumors that aren't destined to be fatal. But some tumors are prone to becoming aggressive and spreading beyond the prostate, making them difficult to treat and life-threatening. Currently, doctors have limited ability to predict which newly diagnosed tumors will progress slowly and which will probably undergo dangerous spread.

Medicine

Channels:

Cell Cycle-Blocking Drugs Can Shrink Tumors by Enlisting Immune System in Attack on Cancer, Study Finds

• Study explains why CDK4/6 inhibitors can shrink tumor in some advanced breast cancers • CDK4/6 inhibitors trigger the immune system to attack tumor cells • CDK4/6 inhibitors can also enhance anti-cancer effect of immunotherapy agents

Medicine

Channels:

Dana Farber Cancer Institute

Dana-Farber/Brigham and Women's Cancer Center the Best in the Region for Cancer Care for 17th Year

Dana-Farber /Brigham and Women's Cancer Center is ranked no. 4 in cancer by U.S. News and World Report.

Medicine

Channels:

Integrative Medicine, Cancer, Meditation, yoga, Art Therapy, Music Therapy

Dana-Farber Debuts New Name, State-of-the-Art Facility for Integrative Therapies

The Dana-Farber Cancer Institute is pleased to announce the opening of the new Leonard P. Zakim Center for Integrative Therapies and Healthy Living, underscoring Dana-Farber’s commitment to providing cutting-edge patient therapies and support for the “whole person” during and after treatment. Increasing data has indicated that integrative therapies can help alleviate side effects of cancer therapy.

Medicine

Science

Channels:

Cancer, Research, Biotech

Four Dana-Farber Researchers Awarded Prestigious “Outstanding Investigator Awards” by National Cancer Institute

The National Cancer Institute (NCI) has awarded four Dana-Farber Cancer Institute researchers with Outstanding Investigator Awards (OIA) for ongoing progressive research within their respective areas of study.

Science

Channels:

Cancer, Innovation, Biotech, Research

Dana-Farber Cancer Institute Names Lesley Solomon SVP, Chief Innovation Officer

LesleySolomon2.jpg

Dana-Farber Cancer Institute has named Lesley Solomon to the newly-created position of senior vice president for innovation and chief innovation officer. Solomon has been serving as executive director of the Brigham Innovation Hub at Brigham and Women’s Hospital and director of strategy and innovation in the Brigham Research Institute.

Medicine

Channels:

Dana Farber Cancer Institute, AML, Leukemia, Acute Myeloid Leukemia, Cancer, Blood Cancers, FDA, Chemotherapy

Backed by Dana-Farber Research, FDA Approves New AML Drug

A targeted drug whose clinical testing was led by Richard Stone, MD, of Dana-Farber Cancer Institute, has become the first new treatment for newly diagnosed acute myeloid leukemia (AML) in more than 25 years.

Medicine

Channels:

Health, Cancer, Disparties, Community

Dana-Farber/Harvard Cancer Center Leader Wins 'Reducing Health Disparities Award' From Mass Medical Society

Karen Burns White, Deputy Associate Director of Dana-Farber/Harvard Cancer Center’s (DF/HCC) Initiative to Eliminate Cancer Disparities (IECD) since 2001, has been honored by the Massachusetts Medical Society as the 2017 recipient of the society’s Reducing Health Disparities Award. The honor recognizes an individual who has made outstanding contributions to reducing health disparities due to race, socioeconomic status, age, education, or sexual orientation.







Chat now!